Oncology
Breast Cancer Just Proved Why Biomarker Selection Matters
Camizestrant failed to significantly improve progression-free survival in an unselected first-line ER-positive, HER2-negative population in SERENA-4, only days after FDA approved it for patients with emerging ESR1 mutations. The contrast is a precision-medicine lesson in real time.
An ADC Steps Into the First-Line Gap in Triple-Negative Breast Cancer
Alpha Radioligand Therapy Moves Prostate Cancer Into a New Infrastructure Test
AI Pathology Starts Moving Toward Treatment Selection
AI Multiomics Moves Into the Trial Stratification Layer
A New CELMoD Raises the Bar in Relapsed Myeloma
IPM Alliance launches at the World Health Assembly in Geneva
IAPM Launches Oncology Pillar at ASCO: Closing the Gap Between Cancer Breakthroughs and Patient Access
WHA 2026: WHO resolution moves precision medicine onto the global health policy agenda
ASCO 2026: Pancreatic cancer gets its precision medicine moment
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Oncology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases